Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of two active pharmaceutical ingredients: - **Penicillin VK (Penicillin V Potassium)** is a narrow-spectrum beta-lactam antibiotic used primarily to treat infections caused by susceptible gram-positive bacteria, such as streptococcal infections. It works by inhibiting bacterial cell wall synthesis, leading to bacterial cell death. - **Haloperidol** is a high-potency first-generation (typical) antipsychotic agent used mainly for the treatment of schizophrenia, acute psychosis, Tourette syndrome, and severe behavioral disorders. It acts primarily through strong antagonism of dopamine D2 receptors in the brain's mesolimbic and mesocortical pathways. Haloperidol also has antagonist effects on Sigma-1 receptors and can induce apoptosis in certain cells. The combination would theoretically provide both antibacterial activity from penicillin VK and antipsychotic effects from haloperidol but there is no standard or approved combined formulation known under this exact name.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on penicillin VK + haloperidol.